Treatment of Neoplastic Meningitis with Radiolabelled Monoclonal Antibodies
Author Information
Author(s): R.P. Moseley, A.G. Davies, R.B. Richardson, M. Zalutsky, S. Carrell, J. Fabre, N. Slack, J. Bullimore, B. Pizer, V. Papanastassiou, J.T. Kemshead, H.B. Coakham, L.S. Lashford
Primary Institution: Brain Tumour Research Laboratory, Department of Neurosurgery, Frenchay Hospital, Bristol, UK
Hypothesis
Can intrathecal administration of radiolabelled monoclonal antibodies effectively treat neoplastic meningitis?
Conclusion
The study found that intrathecal administration of radiolabelled monoclonal antibodies can lead to significant clinical responses in some patients with neoplastic meningitis.
Supporting Evidence
- Six out of nine evaluable patients showed an event-free response lasting between 7 and 26 months.
- Major toxicity included nausea, vomiting, headache, and seizures in some patients.
- Three out of eight evaluable patients developed reversible bone marrow suppression.
Takeaway
Doctors gave special medicine to 15 patients with a type of brain cancer that spreads to the lining of the brain, and some of them got better for a while.
Methodology
Patients received a single intrathecal injection of radiolabelled monoclonal antibodies and were assessed for clinical and tumor responses.
Potential Biases
Potential bias due to the small number of evaluable patients and the subjective nature of clinical assessments.
Limitations
The study had a small sample size and some patients were excluded from evaluation due to various reasons.
Participant Demographics
Patients had a heterogeneous group of tumors including medulloblastoma, gliomas, and melanoma.
Want to read the original?
Access the complete publication on the publisher's website